Navigation Links
Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
Date:4/26/2010

DEERFIELD, Ill., April 26 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT™ (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. Takeda recently announced that the product trade name for dexlansoprazole in the U.S. would be changed from KAPIDEX™ to DEXILANT. The formulation, indication and approved dosages of DEXILANT remain the same as that of KAPIDEX, which was originally approved by the U.S. Food and Drug Administration (FDA) in January 2009. After receiving reports of dispensing errors with KAPIDEX, Takeda, in coordination with the FDA, determined that in the interest of patient safety a name change would be the best way to minimize future errors.  

DEXILANT is a once-daily, oral medication indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication.

"Takeda's response to this situation further demonstrates our commitment to patient safety. We are working to ensure a seamless transition from KAPIDEX to DEXILANT to mitigate any disruption to patient care," said Tim Rudolphi, vice president of marketing at Takeda. "Over the past several months, we conducted a comprehensive communication plan to educate pharmacists, reaching out to more than 45,000 pharmacies, and other health care professionals, including all major prescription insurers and drug wholesalers, about the name change. Today we will begin expanding these efforts to also reach consumers."
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Leading Varian-Equipped Proton Therapy Center Treats 100th Patient
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
5. New Proton Therapy Equipment Enables More Tumors to be Treated
6. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
7. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
8. Neurocrine Advances VMAT2 Inhibitor Program
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
11. TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
(Date:8/27/2014)... Decision Resources Group finds that the intense ... health system and hospital sector in recent ... Methodist Le Bonheur Healthcare and Baptist Memorial Health Care ... care. In addition, a national contract recently signed between ... enrollment in the Memphis market, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... Home Care Assistance of Scottsdale , ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/27/2014)... of clinical trial participation in the largest ongoing observational ... are not representative of the larger patient base, according ... Dr. Jay Udell. The study authors call into question ... population, and suggest the use of broader enrollment criteria ... "We know that clinical trials can be tremendously expensive ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Cash House ... impact on the overall upkeep of the shelter including new ... importantly helping to change the lives of each youth who ... 35 bed emergency shelter for youth ages 16-25. Not only ... many programs and resources for the youth who come through ...
(Date:8/27/2014)... Lighthouse Payment Services Inc ., a leader ... exhibit its image-based lockbox services at the Independent Bankers ... in beautiful Lake Placid, New York from September 7th ... at the Lake Placid Convention Center and will feature ... addition to a variety of vendors exhibiting the latest ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3
... (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. ... active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, ... LT-NS001 is a novel, patented NCE prodrug of the ... developed to significantly reduce the GI safety risks, including ...
... 30-Year Finance Executive Veteran Adds Public Accounting, Executive ... Smith announced today that Dave Watkins has been ... responsible for overseeing all Company financial functions, including ... forecasts and tax planning. H. D. Smith ...
... Time Spent Caring for Parents with Alzheimer,s in Heartfelt New ... memoirs, "36 Days Apart: A memoir of a daughter, her ... Life, Love and Death" ( published by AuthorHouse ... of her mother and father, both of whom were diagnosed ...
... - Discovery Health,s Seventh Annual Programming Event Presents Baby ... 14, through Friday, June 19 - SILVER SPRING, Md., ... the third week of June to deliver the network,s ... pregnancies, to surprise deliveries, to expectant mothers big and ...
... prebiotics market is diversifying and expanding in ... and beverage industry, with several exciting developments ... and the expansion of prebiotic ingredients into ... and meat products.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New prebiotic ...
... of 14 Hydroxycut products, consumers who have suffered injuries from using ... products liability attorney to determine if he/she is eligible for compensation. ... , ... San Diego, CA (PRWEB) May 26, 2009 ...
Cached Medicine News:Health News:Medinox Announces Clinical Results of Naproxen Prodrug 2Health News:H. D. Smith Appoints Dave Watkins Chief Financial Officer 2Health News:New Memoir Details Effects of Alzheimer's on Family 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 3Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 2Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 3Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 5Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 6Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 7Health News:LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: